---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-044795"
form_type: "8-K"
ticker: null
cik: "0001850838"
company_name: "Omega Therapeutics, Inc."
filed_at: "2024-04-16T23:59:59+00:00"
generated_at: "2026-06-03T22:24:14.874053+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Omega Therapeutics CFO Joshua Reed to depart May 31; Barbara Chan named successor

## Summary
- Joshua Reed's employment terminated effective May 31, 2024; severance and extended option exercisability.
- Barbara Chan, SVP Finance, appointed principal financial officer and principal accounting officer effective May 31.
- Chan also becomes Treasurer; has been at Omega since May 2020.
- Prior role: VP Finance and CAO at Aegerion Pharmaceuticals (2016-2019).
- Chan holds B.S. and M.S. in Accounting and Taxation from Bentley University.

## SEC filing metadata
- accession: 0000950170-24-044795
- form_type: 8-K
- cik: 0001850838
- company_name: Omega Therapeutics, Inc.
- filed_at: 2024-04-16T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850838/000095017024044795/0000950170-24-044795-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850838/000095017024044795/omga-20240410.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-044795
- JSON: https://secwatch.observer/filing/0000950170-24-044795.json
- Plain text: https://secwatch.observer/filing/0000950170-24-044795.txt

## Key facts
- Executive change
  Barbara Chan was appointed as principal financial officer and principal accounting officer at Omega Therapeutics, Inc..
  - Action: designated
  - Role: principal financial officer and principal accounting officer
  source text: On April 16, 2024, the Board of Directors of the Company designated Barbara Chan, the Company’s Senior Vice President, Finance, as its principal financial officer and principal accounting officer, in each case effective on the Effective Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1850838/000095017024044795/0000950170-24-044795-index.htm
- Executive change
  Joshua Reed was terminated as Chief Financial Officer at Omega Therapeutics, Inc..
  - Action: terminated
  - Role: Chief Financial Officer
  source text: On April 10, 2024, Omega Therapeutics, Inc. (the “Company”) and Joshua Reed, the Company’s Chief Financial Officer, agreed to terminate his employment effective as of May 31, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1850838/000095017024044795/0000950170-24-044795-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.